Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer
- Author:
So Young KIM
1
;
Kyung Un CHOI
;
Chungsu HWANG
;
Hyung Jung LEE
;
Jung Hee LEE
;
Dong Hoon SHIN
;
Jee Yeon KIM
;
Mee Young SOL
;
Jae Ho KIM
;
Ki Hyung KIM
;
Dong Soo SUH
;
Byung Su KWON
Author Information
- Publication Type:Original Article
- Keywords: Ovarian epithelial carcinoma; CD109; Prognosis
- MeSH: Cell Line, Tumor; Drug Therapy; Humans; Polymerase Chain Reaction; Prognosis; Recurrence; Risk Factors; RNA, Messenger
- From:Journal of Pathology and Translational Medicine 2019;53(4):244-252
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Ovarian epithelial cancer (OEC) is the second-most common gynecologic malignancy. CD109 expression is elevated in human tumor cell lines and carcinomas. A previous study showed that CD109 expression is elevated in human tumor cell lines and CD109 plays a role in cancer progression. Therefore, this study aimed to determine whether CD109 is expressed in OEC and can be useful in predicting the prognosis. METHODS: Immunohistochemical staining for CD109 and reverse transcription-quantitative polymerase chain reaction was performed. Then we compared CD109 expression and chemoresistance, overall survival, and recurrence-free survival of OEC patients. Chemoresistance was evaluated by dividing into good-response group and poor-response group by the time to recurrence after chemotherapy. RESULTS: CD109 expression was associated with overall survival (p = .020), but not recurrence-free survival (p = .290). CD109 expression was not an independent risk factor for overall survival due to its reliability (hazard ratio, 1.58; p = .160; 95% confidence interval, 0.82 to 3.05), although we found that CD109 positivity was related to chemoresistance. The poor-response group showed higher rates of CD109 expression than the good-response group (93.8% vs 66.7%, p = .047). Also, the CD109 mRNA expression level was 2.88 times higher in the poor-response group as compared to the good-response group (p = .001). CONCLUSIONS: Examining the CD109 expression in patients with OEC may be helpful in predicting survival and chemotherapeutic effect.
